CASI Pharmaceuticals administers first FOLOTYN dose in China for PTCL treatment
In a significant stride toward addressing the critical medical needs of peripheral T-cell lymphoma (PTCL) patients in China, CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a trailblazer ... Read More
Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL
Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
Takeda gets extended EC approval for ADCETRIS in sALCL
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More
Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma
Seattle Genetics' Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the ... Read More